Researchers at the University of Washington and the Fred Hutchinson Cancer Center have reported the development of an in vivo model of macrophage infiltration of the tumor microenvironment (TME) in melanoma and how infiltration affects tumor progression.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and > 80% of cases are associated with the most common risk factor of liver cirrhosis.

Because dysregulated energy metabolism is common across both familial and sporadic forms of amyotrophic lateral sclerosis (ALS), targeting energy production is believed to have therapeutic potential. University of Edinburgh and University of Oxford researchers have tested modulating the expression of the glycolysis enzyme phosphoglycerate kinase 1 (PGK1) in preclinical models of ALS by using terazosin, a PGK1 activator, with the aim of confirming it as a therapeutic target in the treatment of the disease.

The FDA has granted rare pediatric disease designation to iECURE's lead product candidate GTP-506 for the treatment of ornithine transcarbamylase (OTC) deficiency in a pediatric population.

Parkinson's disease (PD) is the second most common neurodegenerative disorder and is characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the abnormal accumulation and aggregation of alpha-synuclein.

Ascentage Pharma has discovered sulfonyl benzamide derivatives acting as apoptosis regulator Bcl-2 and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer.

The Consiglio Nazionale delle Ricerche and the Societa Industria Farmaceutica Italiana SpA (SIFI) have described new peptides acting as vascular endothelial growth factor receptor 1 (VEGFR-1; FLT1) and VEGFR-2 inhibitors reported to be useful for the treatment of cancer, choroidal neovascularization, hematopoiesis disorders, macular edema, central retinal vein occlusion, central serous retinopathy, diabetic retinopathy and wet macular degeneration, among other disorders.

Yangtze River Pharmaceutical Group and Shanghai Haiyan Pharmaceutical Technology have divulged new morpholine derivatives acting as P2X purinoceptor 3 (P2RX3; P2X3) antagonists and reported to be useful for the treatment of cancer, pain, cough, depression, anxiety and genitourinary, gastrointestinal and immunological disorders, among other disorders.

Floratek has presented new chromen-4-one derivatives comprising a phosphonium quaternary group reported to be useful for the treatment of cancer.

Janssen and Johnson & Johnson have divulged dihydropyrimidine derivatives reported to be useful for the treatment of hepatitis B virus (HBV) infections.